| |
PATIENT REQUEST FORMS
| |
PSMA-directed molecular imaging in prostate cancer
PET / CT examination with 68 Ga-PSMA ligands
A new, highly sensitive marker for PET / CT has now been introduced at the Clinic for Nuclear Medicine at Saarland University Hospital in Homburg in order to identify tumor foci in patients with prostate cancer more precisely. The radiopharmaceutical gallium-68-PSMA ligand binds to prostate-specific membrane antigen (PSMA) on the surface of tumor cells and thus enables imaging with very high contrast. In the process, the smallest tumor settlements can be discovered that could escape conventional imaging.
.